Article thumbnail

Bench-to-bedside review: Clostridium difficile colitis

By Carolyn V Gould and L Clifford McDonald

Abstract

In recent years, the incidence and severity of Clostridium difficile-associated disease (CDAD) have increased dramatically. Beginning in 2000, widespread regional outbreaks associated with a previously uncommon hypervirulent strain of C. difficile have occurred in North America and Europe. Most likely because of increased toxin production as well as other virulence factors, this epidemic strain has caused more severe and refractory disease leading to complications, including intensive care unit admission, colectomies, and death. Worldwide increasing use of fluoroquinolones and cephalosporins has likely contributed to the proliferation of this epidemic strain, which is highly resistant to both. The elderly have been disproportionately affected by CDAD, but C. difficile has also recently emerged in populations previously considered to be at low risk, including healthy outpatients and peripartum women, although it is unknown if these cases are related to the epidemic strain. Nevertheless, transmission within hospitals is the major source of C. difficile acquisition, and previous or concurrent antimicrobial use is almost universal among cases. Applying current evidence-based strategies for management and prevention is critically important, and clinicians should maintain an awareness of the changing epidemiology of CDAD and take measures to reduce the risk of disease in patients

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2374604
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol
  2. (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
  3. (2007). and the Healthcare Infection Control Practices Advisory Committee: Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings
  4. (1978). Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.
  5. (2005). Avesani V: Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture.
  6. (1989). Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet
  7. (2007). Bulpitt CJ: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ
  8. (2005). C: Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis
  9. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007, 45(Suppl 2):S122-S128.
  10. (2003). Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med
  11. (1994). Clostridium difficile colitis.
  12. (2007). Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol
  13. (1995). Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol
  14. (2006). Clostridium difficile-associated disease: new challenges from an established pathogen.
  15. (2001). CP: Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet
  16. (2000). CP: Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
  17. (2003). CP: Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun
  18. (2002). CP: Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis
  19. (1997). CP: Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut
  20. (1991). D: Clostridium difficile-associated diarrhea in a region of Quebec from
  21. (2006). DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis
  22. (1991). DDH: Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.
  23. (2004). Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital.
  24. (2006). Emergence of Clostridium difficile-associated disease
  25. (2005). et al.: Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains.
  26. (1999). et al.: Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.
  27. (2007). et al.: Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities.
  28. (2006). et al.: Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis
  29. (2007). for the Polymer Alternative for CDAD Treatment (PACT) Investigators: Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD).
  30. (2006). Friedenberg F: Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea.
  31. (2004). Friedenberg F: Factors associated with failure of metronidazole in Clostridium difficile-associated disease.
  32. (1992). Gerding DN: Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.
  33. (2005). Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile.
  34. (1998). Gerding DN: Clostridium difficile-associated diarrhea. Clin Infect Dis
  35. (2007). Gerding DN: Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis
  36. (1990). Gerding DN: Nosocomial Clostridium difficile colonisation and disease. Lancet
  37. (1998). Gerding DN: Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet
  38. (1996). Graninger W: Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis
  39. (1999). Greenberg RN: Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol
  40. (2002). Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/ APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol
  41. (2006). Havill NL: Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol
  42. (2006). Henwick S: Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada.
  43. (2006). Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun
  44. (2007). Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg
  45. (1996). Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis
  46. (1993). Intracolonic vancomycin for pseudomembranous colitis.
  47. (2002). Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut
  48. (1981). Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology
  49. (2006). JF: Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis
  50. (1995). JG: Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med
  51. (1983). Jr: Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficileassociated diarrhoea and colitis. Lancet
  52. (2007). KC: Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for the detection of toxigenic Clostridium difficile.
  53. (2007). L: Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis
  54. (2007). LC: Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol
  55. (2005). LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet
  56. (2002). LE: Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol
  57. (2001). LH: Rifampin non-susceptibility associated with epidemic BI/NAP1 C. difficile isolates in
  58. (1995). listed: Recommendations for preventing the spread of vancomycin resistance. recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm and Rep
  59. (2000). LJ: Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope.
  60. (1992). LL: Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays.
  61. (2002). LM: Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis
  62. (2000). LM: Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis
  63. (1990). LR: Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.
  64. (2007). MB: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis
  65. (2005). MH: Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
  66. (2002). Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol
  67. (2006). Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med
  68. (2005). Peláez TT: Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis
  69. (2001). Petit JC: Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect
  70. (2000). Petit JC: Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.
  71. (2005). Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ
  72. (2003). Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis
  73. (2007). Rifampin susceptibility by agar dilution and Etest predicts susceptibility to rifaximin in Clostridium difficile.
  74. (2005). Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol
  75. (1998). Risk factors for Clostridium difficile infection.
  76. (2005). RJ: Relatively poor outcome after treatment of ClostridCritical Care
  77. (2006). Safety of probiotics: comparison of two popular strains. BMJ
  78. (2005). Safety, pharmacokinetics and outcomes of PAR-101 in healthy subjects and patients with Clostridium difficile-associated diarrhea.
  79. (2005). Severe Clostridium difficile-associated disease in populations previously at low risk - four states,
  80. (1978). SP: Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet
  81. (2007). SP: Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series.
  82. (1997). Successful control of Clostridium difficile infection in an elderly care unit through use of a restricAvailable online http://ccforum.com/content/12/1/203 Page 7 of 8 (page number not for citation purposes)tive antibiotic policy.
  83. (2002). Surawicz CM: Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
  84. (2004). Tenover FC: Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis
  85. (2000). The role of physical proximity in nosocomial diarrhea. Clin Infect Dis
  86. (1992). Thorne GGM: Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A.
  87. (1998). Timing of surgery for fulminating pseudomembranous colitis.
  88. (2004). TS: Ramoplanin vs. vancomycin in the treatment of Clostridium difficile diarrhea: a phase 2 study.
  89. (1993). Tsimidis K: Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis
  90. (1989). WE: Nosocomial acquisition of Clostridium difficile infection.
  91. (1987). WR: Secular trends in hospital-acquired Clostridium difficile disease in the United States,